Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma

Katherine M. Sheehan, Valerie S. Calvert, Elaine W. Kay, Yiling Lu, David Fishman, Virginia Espina, Joy Aquino, Runa Speer, Robyn Araujo, Gordon B. Mills, Lance A. Liotta, Emanuel F. Petricoin, Julia D. Wulfkuhle

    Research output: Contribution to journalArticle

    254 Scopus citations

    Abstract

    Cancer can be defined as a deregulation or hyperactivity in the ongoing network of intracellular and extracellular signaling events. Reverse phase protein microarray technology may offer a new opportunity to measure and profile these signaling pathways, providing data on post-translational phosphorylation events not obtainable by gene microarray analysis. Treatment of ovarian epithelial carcinoma almost always takes place in a metastatic setting since unfortunately the disease is often not detected until later stages. Thus, in addition to elucidation of the molecular network within a tumor specimen, critical questions are to what extent do signaling changes occur upon metastasis and are there common pathway elements that arise in the metastatic microenvironment. For individualized combinatorial therapy, ideal therapeutic selection based on proteomic mapping of phosphorylation end points may require evaluation of the patient's metastatic tissue. Extending these findings to the bedside will require the development of optimized protocols and reference standards. We have developed a reference standard based on a mixture of phosphorylated peptides to begin to address this challenge.

    Original languageEnglish (US)
    Pages (from-to)346-355
    Number of pages10
    JournalMolecular and Cellular Proteomics
    Volume4
    Issue number4
    DOIs
    StatePublished - Apr 2005

    ASJC Scopus subject areas

    • Analytical Chemistry
    • Biochemistry
    • Molecular Biology

    Fingerprint Dive into the research topics of 'Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y., Fishman, D., Espina, V., Aquino, J., Speer, R., Araujo, R., Mills, G. B., Liotta, L. A., Petricoin, E. F., & Wulfkuhle, J. D. (2005). Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Molecular and Cellular Proteomics, 4(4), 346-355. https://doi.org/10.1074/mcp.T500003-MCP200